Associated Papers
A novel iPSC model of Bryant-Li-Bhoj neurodevelopmental/neurodegenerative syndrome demonstrates the role of histone H3.3 in chromatin dynamics, neuronal differentiation, and maturation.
Sangree AK et al.
Journal of Translational Medicine, 2026
Integrated high-resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34-mutant reveals universal TP53 abnormalities.
Trejo-Lopez JA et al.
Brain Pathology (zurich, Switzerland), 2026
Redefining Treatment Paradigms for Glioma in Adolescents and Young Adults: Population-Based Evidence for Molecular Classification.
Qu S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
H3-3A gene mutation analysis in giant cell tumor of bone and its histologic mimics: A single institutional study from India.
Uppin SG et al.
Annals of Diagnostic Pathology, 2026
H3.3G34W immunohistochemistry negative giant cell tumour of bone. Extended analysis of 35 such cases from a single institution in India.
Uppin SG et al.
Virchows Archiv : an International Journal of Pathology, 2025
Diffuse hemispheric glioma, H3 G34-mutant, a single centre experience and histopathological analysis.
Amer F et al.
Virchows Archiv : an International Journal of Pathology, 2025
A novel iPSC model of Bryant-Li-Bhoj neurodevelopmental/neurodegenerative syndrome demonstrates the role of histone H3.3 in chromatin dynamics, neuronal differentiation, and maturation.
Sangree AK et al.
Biorxiv : the Preprint Server for Biology, 2025
Implications of canonical histone H3.1 and histone variant H3.3 in cancer.
Wu P et al.
Open Biology, 2025
Diffuse Hemispheric Glioma, H3 G34-Mutant With Prominent Perivascular Invasion in a Middle-Aged Man: A Case Report and Literature Review of Middle-Aged and Elderly Cases.
Yuzawa S et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2025
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.
Le Rhun E et al.
Neuro-oncology, 2025
Clinical pathological characteristics correlation of H3F3A gene mutation in giant cell tumor of bone: a study of 96 cases.
Du J et al.
Translational Cancer Research, 2025
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications.
Haase S et al.
Trends in Cancer, 2024
H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications.
Angelico G et al.
Cancers, 2024
Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.
Andrade AF et al.
Nature Communications, 2024
Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals.
Layo-Carris DE et al.
European Journal of Human Genetics : Ejhg, 2024
Beyond the Usual Suspects: Examining the Role of Understudied Histone Variants in Breast Cancer.
Dhahri H et al.
International Journal of Molecular Sciences, 2024
Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
Donev K et al.
Journal of Neuropathology and Experimental Neurology, 2024
Histone 3.3-related chromatinopathy: missense variants throughout H3-3A and H3-3B cause a range of functional consequences across species.
Bryant L et al.
Human Genetics, 2024
Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.
Giacomini G et al.
Nucleic Acids Research, 2024
Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
Hayashi T et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
Nazem A et al.
Journal of Neuropathology and Experimental Neurology, 2023
Histone mutations in cancer.
Espinoza Pereira KN et al.
Biochemical Society Transactions, 2023
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Wood MD et al.
Acta Neuropathologica Communications, 2023
Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas.
Jane EP et al.
Molecular Oncology, 2023
A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA et al.
Acta Neuropathologica, 2023
Integrated genetic profiling of archival pediatric high-grade glial tumors and reassessment with 2021 WHO classification of paediatric CNS tumours.
Cooley LD et al.
Cancer Genetics, 2023
H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
Lavrador JP et al.
Acta Neurochirurgica, 2023
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
Ocasio JK et al.
Cancer Metastasis Reviews, 2023
Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration.
Khazaei S et al.
Cell, 2023
Diagnostic value of H3F3A mutation and clinicopathological features of giant cell tumours in non-long bones.
Luo Y et al.
Journal of Bone Oncology, 2023
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
Haase S et al.
The Journal of Clinical Investigation, 2022
Germline MUTYH mutations and high-grade gliomas: Novel evidence for a potential association.
Bedics G et al.
Genes, Chromosomes & Cancer, 2022
A Targeted Next-Generation Sequencing Panel to Genotype Gliomas.
Guarnaccia M et al.
Life (basel, Switzerland), 2022
Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.
Ishihara S et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L et al.
Annals of Diagnostic Pathology, 2022
Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas.
Wolter M et al.
Acta Neuropathologica Communications, 2022
Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series.
Buccoliero AM et al.
Genes, 2022
High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
Hu W et al.
Journal of Translational Medicine, 2022
Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
Wang L et al.
The American Journal of Surgical Pathology, 2022
Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone.
Wągrodzki M et al.
International Journal of Molecular Sciences, 2022
Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation.
Donigian S et al.
Journal of Pediatric Hematology/oncology, 2022
Gene of the month: H3F3A and H3F3B.
Aldera AP et al.
Journal of Clinical Pathology, 2022
Chromatin mutations in pediatric high grade gliomas.
Voon HPJ et al.
Frontiers in Oncology, 2022
Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
Arakaki AKS et al.
Neuro-oncology, 2021
Glioblastoma with primitive neuronal component: An immunohistochemical study and review of literature.
Poyuran R et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, 2021
Prognostic and Predictive Biomarkers in Gliomas.
Śledzińska P et al.
International Journal of Molecular Sciences, 2021
Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Katagi H et al.
Neuro-oncology, 2021
A common classification framework for histone sequence alterations in tumours: an expert consensus proposal.
Leske H et al.
The Journal of Pathology, 2021